PETER CESTODIO: Open Payments
NPI 1780373886 · STURBRIDGE, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$968 in 45 payments from 13 companies in 2025. Trend: 2023 $190 · 2024 $1,273 · 2025 $968
Food & beverage: $873Education: $95
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $252 |
| Janssen Biotech, Inc. | 9 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Aimmune Therapeutics, Inc. | 3 | $69 |
| QOL Medical, LLC | 2 | $69 |
| Lilly USA, LLC | 2 | $54 |
| Gilead Sciences, Inc. | 2 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| PFIZER INC. | 2 | $35 |
Products named: TREMFYA, LINZESS, ENTYVIO, SKYRIZI, VOWST, Sucraid, OMVOH, DUPIXENT.
Industry payments across MA — which companies pay providers there.
